<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351816</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00731-52</org_study_id>
    <nct_id>NCT03351816</nct_id>
  </id_info>
  <brief_title>Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation</brief_title>
  <acronym>Biorhythm</acronym>
  <official_title>Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Biorhythm study aims to investigate the utility of new biomarkers (e.g. MR proANP, ST2)
      measured pre-procedure for the prediction of procedural success in patients with atrial
      fibrillation undergoing cardioversion or ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, multicentre study of patients with paroxystic or
      persistent atrial fibrillation scheduled to undergo cardioversion or ablation of AF in
      routine practice. We will measure serum levels of MR proANP and ST2 pre-procedure to attempt
      to identify a threshold that carries prognostic value for procedural success (maintenance of
      sinus rhythm at one year).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence of atrial fibrillation, atrial tachycardia or flutter documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent atrial fibrillation</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrence of atrial fibrillation, atrial tachycardia or flutter documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpitations</measure>
    <time_frame>12 months</time_frame>
    <description>Any episode of palpitation occurring during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Hospital admission related to atrial fibrillation, atrial tachycardia or flutter during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>12 months</time_frame>
    <description>Need for repeat ablation during follow-up in patients who underwent ablation of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioversion</measure>
    <time_frame>12 months</time_frame>
    <description>Need for electric or medical cardioversion during follow-up (all patients, regardless of initial intervention type)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cardioversion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of atrial fibrillation</intervention_name>
    <description>Pulmonary vein isolation by radiofrequency or cryoablation.</description>
    <arm_group_label>Ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <description>External electric shock delivery under general anesthesia.</description>
    <arm_group_label>Cardioversion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with paroxystic or persistent atrial fibrillation for whom a decision to
             perform ablation is made.

          -  Patients with persistent atrial fibrillation for whom a decision to perform
             cardioversion is made.

          -  Patients with social security coverage, or beneficiary thereof.

          -  Patients who provide written informed consent.

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;80 years

          -  Patients with significant valvular heart disease defined as symptomatic aortic valve
             disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade
             3/4 or 4/4

          -  Patients with pulmonary arterial hypertension &gt;45 mmHg on echocardiography

          -  Patients with chronic respiratory disease, chronic obstructive pulmonary disease stage
             II, III or IV.

          -  Patients with a left ventricular ejection fraction &lt;45%

          -  Patients with recent (&lt;1 month) acute decompensation of heart failure

          -  Patients with recent (&lt;1 month) acute coronary syndrome

          -  Anemia (hemoglobin &lt;10 g/dL)

          -  Pregnant or lactating women

          -  Patients with anticipated poor compliance, as assessed by the study investigator

          -  Patients within the exclusion period of another clinical study

          -  Patients under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Meneveau, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Badoz, MD</last_name>
    <phone>33381668185</phone>
    <email>mbadoz@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Guignier, MD</last_name>
    <phone>33381668185</phone>
    <email>aguignier@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas F. Meneveau, MD</last_name>
      <phone>33381668624</phone>
      <email>nicolas.meneveau@univ-fcomte.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fiona Ecarnot, MSc</last_name>
      <phone>33381668539</phone>
      <email>fiona.ecarnot@univ-fcomte.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre Guignier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Fran√ßois Mitterand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel Laurent, MD, PhD</last_name>
      <email>gabriel.laurent@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian De Chillou, MD, PhD</last_name>
      <email>c.dechillou@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

